Mayo specialist for Cytopia
Wednesday, 30 July, 2008
Cytopia [ASX: CYT] has appointed a study chair for Phase I clinical trials of its new JAK2 enzyme inhibitor.
Dr Ayalew Tefferi is professor of medicine in haematology at the Mayo Clinic College of Medicine in the US.
JAK2 is a mutant enzyme which occurs in myelofibrosis patients, a disorder which causes bone marrow to be replaced by fibrous scar tissue. JAK2 can also cause other blood disorders, many of which can lead to conditions such as leukemia.
Cytopia expects to be ready to file an Investigational New Drug application for the treatment with the US FDA by the end of the year.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
